{"id":44090,"date":"2025-10-22T19:45:19","date_gmt":"2025-10-22T11:45:19","guid":{"rendered":"https:\/\/flcube.com\/?p=44090"},"modified":"2025-10-22T19:45:20","modified_gmt":"2025-10-22T11:45:20","slug":"fosun%e2%80%91henlius-announces-26-8%e2%80%91month-median-os-for-hetronifly-plus-chemo-in-advanced-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44090","title":{"rendered":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC"},"content":{"rendered":"\n<p><strong>Fosun Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>)<\/strong> subsidiary <strong>Shanghai Henlius Biotech, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>)<\/strong> unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the <strong>2025 European Society for Medical Oncology (ESMO) Congress<\/strong>. The results confirm that <strong>Hetronifly (Serplulimab)<\/strong>, an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a <strong>median overall survival (mOS) of 26.8\u202fmonths<\/strong> when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII Final Analysis<\/strong> \u2013 Presented as a Late\u2011Breaking Abstract (LBA) with the first oral presentation of OS data.<\/li>\n\n\n\n<li><strong>Median OS<\/strong> \u2013 26.8\u202fmonths for Serplulimab\u202f+\u202fchemo vs. 18.0\u202fmonths for standard chemotherapy (HR\u202f=\u202f0.67; 95\u202f%\u202fCI\u202f0.52\u20110.85; P\u202f&lt;\u202f0.001).<\/li>\n\n\n\n<li><strong>Survival Benefit<\/strong> \u2013 44\u202f% reduction in risk of death over the study period.<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong> \u2013 Approved in China for first\u2011line chemo combinations in sq\u2011NSCLC, ES\u2011SCLC, ESCC, and nsq\u2011NSCLC.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-hetronifly-serplulimab\"><strong>About Hetronifly (Serplulimab)<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Independent Development<\/strong> \u2013 First\u2011in\u2011class anti\u2011PD\u20111 antibody from Henlius.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong> \u2013 Blocks PD\u20111\/PD\u2011L1 interaction, reactivating T\u2011cell mediated tumor killing.<\/li>\n\n\n\n<li><strong>Global Pipeline<\/strong> \u2013 Under investigation in multiple tumor types, including colorectal, gastric, and head\u2011and\u2011neck cancers.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implications-for-oncology-practice\"><strong>Implications for Oncology Practice<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Extended Survival<\/strong> \u2013 Provides clinicians with a robust first\u2011line option for advanced nsq\u2011NSCLC.<\/li>\n\n\n\n<li><strong>Patient Benefit<\/strong> \u2013 26.8\u2011month OS represents a meaningful improvement over existing chemo\u2011only regimens.<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong> \u2013 Reinforces Henlius\u2019s portfolio in the highly competitive lung\u2011cancer immunotherapy arena.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44091,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,159,270,862,18,892],"class_list":["post-44090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-fosun-pharmaceutical","tag-henlius-biotech","tag-hkg-2696","tag-pd-1-l1","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44090\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44090\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T11:45:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T11:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC\",\"datePublished\":\"2025-10-22T11:45:19+00:00\",\"dateModified\":\"2025-10-22T11:45:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090\"},\"wordCount\":259,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2202.webp\",\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"Fosun Pharmaceutical\",\"Henlius Biotech\",\"HKG: 2696\",\"PD-1\\\/L1\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44090#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44090\",\"name\":\"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2202.webp\",\"datePublished\":\"2025-10-22T11:45:19+00:00\",\"dateModified\":\"2025-10-22T11:45:20+00:00\",\"description\":\"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44090\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2202.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2202.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44090#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44090","og_locale":"en_US","og_type":"article","og_title":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC","og_description":"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.","og_url":"https:\/\/flcube.com\/?p=44090","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T11:45:19+00:00","article_modified_time":"2025-10-22T11:45:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44090#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44090"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC","datePublished":"2025-10-22T11:45:19+00:00","dateModified":"2025-10-22T11:45:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44090"},"wordCount":259,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","keywords":["Academic conference","Cancer","Clinical trial results","Fosun Pharmaceutical","Henlius Biotech","HKG: 2696","PD-1\/L1","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44090#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44090","url":"https:\/\/flcube.com\/?p=44090","name":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44090#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44090#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","datePublished":"2025-10-22T11:45:19+00:00","dateModified":"2025-10-22T11:45:20+00:00","description":"Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase\u202fIII ASTRUM\u2011002 data at the 2025 European Society for Medical Oncology (ESMO) Congress. The results confirm that Hetronifly (Serplulimab), an independently developed anti\u2011PD\u20111 monoclonal antibody, achieves a median overall survival (mOS) of 26.8\u202fmonths when combined with chemotherapy for first\u2011line treatment of advanced non\u2011squamous non\u2011small\u2011cell lung cancer (nsq\u2011NSCLC), surpassing the two\u2011year survival threshold.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44090#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44090"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44090#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","width":1080,"height":608,"caption":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44090#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun\u2011Henlius Announces 26.8\u2011Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2202.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44090"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44090\/revisions"}],"predecessor-version":[{"id":44092,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44090\/revisions\/44092"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44091"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}